To include your compound in the COVID-19 Resource Center, submit it here.

Durect's Posimir misses in Phase III for postsurgical pain

Durect Corp. (NASDAQ:DRRX) said Posimir bupivacaine (SABER-Bupivacaine) missed the primary endpoint in the Phase III PERSIST trial to treat postsurgical pain. The company had expected the trial to support an NDA resubmission following its receipt

Read the full 359 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE